BICILLIN L-A SUSPENSION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

PENICILLIN G BENZATHINE

থেকে পাওয়া:

PFIZER CANADA ULC

এটিসি কোড:

J01CE08

INN (আন্তর্জাতিক নাম):

BENZATHINE BENZYLPENICILLIN

ডোজ:

1200000UNIT

ফার্মাসিউটিকাল ফর্ম:

SUSPENSION

রচনা:

PENICILLIN G BENZATHINE 1200000UNIT

প্রশাসন রুট:

INTRAMUSCULAR

প্যাকেজ ইউনিট:

10X2ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

NATURAL PENICILLINS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0134766002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2007-02-12

পণ্য বৈশিষ্ট্য

_ _
_Bicillin_
_®_
_ L-A_
_(penicillin G benzathine) – Product Monograph _
_Page 1 of 23_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BICILLIN
® L-A
Penicillin G benzathine
1,200,000 IU per 2 mL suspension for injection, for intramuscular
injection only
Antibiotic
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5
Date of Initial Authorization:
Feb 12, 2007
Date of Revision:
Apr 18, 2023
Submission Control Number: 268414
® King Pharmaceuticals Research and Development, Inc.
Pfizer Canada ULC, Licensee
_ _
_Bicillin_
_®_
_ L-A_
_(penicillin G benzathine) – Product Monograph _
_Page 2 of 23_
RECENT MAJOR LABEL CHANGES
3 Serious Warnings and Precautions Box
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recomme